Advertisement

Topics

Insulin Sensitizers on Mitochondrial ATP Production and Mitochondrial ATP Production and Mitochondrial Protein Synthesis on Insulin Resistant Type 2 Diabetes and Obesity

2014-07-23 21:30:02 | BioPortfolio

Summary

An association between insulin resistance and mitochondrial dysfunction has been observed in aging, T2D, and in offspring of patients with T2D. It remains to be determined whether pharmacological agents that enhance insulin sensitivity improve muscle mitochondrial function. If these insulin sensitizers improve muscle mitochondrial functions, there are potential therapeutic opportunities to use these drugs to improve mitochondrial dysfunction such as sarcopenia of aging or obesity. Our previous studies demonstrated that insulin stimulates muscle mitochondrial PS and ATP production. It is therefore likely that increasing insulin action stimulates mitochondrial PS and ATP production. If so, these results argue against mitochondrial dysfunction as a cause for insulin resistance. The secondary measurements will demonstrate the underlying mechanism ? whether changes occur at the level of intracellular signaling, transcription or translation. Furthermore, changes in hepatic fat infiltration and endogenous glucose release will be assessed.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment

Conditions

Type 2 Diabetes

Intervention

metformin, pioglitazone

Location

Mayo Clinic
Rochester
Minnesota
United States
55905

Status

Recruiting

Source

Mayo Clinic

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:30:02-0400

Clinical Trials [5099 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

The purpose of this study is to determine the efficacy of pioglitazone, twice daily (BID), combined with metformin versus pioglitazone taken alone and metformin taken alone in treating Typ...

Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes

The purpose of this study is to determine the efficacy of pioglitazone and metformin combination therapy, once daily (QD), on glycosylated hemoglobin in adults with type 2 diabetes.

Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.

The purpose of this study is to determine the Anti-Inflammation Effects of Pioglitazone, twice daily (BID), and Pioglitazone/Metformin Combination Therapy BID in Type 2 Diabetes Subjects T...

Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

The current study investigates Welchol as add-on therapy to pioglitazone to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with pioglitazone m...

Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients

The study aims to see if there is any significant difference in the cardiovascular outcomes in type 2 diabetes patients who are treated with pioglitazone or Metformin

PubMed Articles [9494 Associated PubMed Articles listed on BioPortfolio]

Chronic systemic inflammation in the pathogenesis of comorbid pathology and it's correction.

Introduction: The paper presents the findings of our own study on the changes of the systemic inflammation in patients with type 2 diabetes mellitus (DM2) and ischemic heart disease (IHD) during the c...

Metformin Improves Peripheral Insulin Sensitivity in Youth with Type 1 Diabetes.

Type 1 diabetes in adolescence is characterized by insulin deficiency and resistance (IR), both thought to increase cardiovascular disease risk. We previously demonstrated adolescents with type 1 diab...

Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra.

Two ratio derivative spectrophotometric methods were performed for the simultaneous analysis of metformin hydrochloride, empagliflozine, linagliptin, and pioglitazone hydrochloride in their synthetic ...

Detecting Pioglitazone Use and Risk of Cardiovascular Events Using Electronic Health Record Data in a Large Cohort of Chinese Patients with Type 2 Diabetes.

Pioglitazone may have a protective effect on cardiovascular disease risk among type 2 diabetes patients but evidence from China is lacking. Our study aimed to investigate the association using massive...

Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin up-titration in treatment of patients with type 2 diabetes: the CompoSIT-M Study.

To characterize the glycemic efficacy and safety of initiation of the DPP-4 inhibitor sitagliptin during metformin dose escalation in participants with type 2 diabetes (T2D) not at HbA1c goal on a sub...

Medical and Biotech [MESH] Definitions

A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of TYPE 2 DIABETES.

A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)

The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

More From BioPortfolio on "Insulin Sensitizers on Mitochondrial ATP Production and Mitochondrial ATP Production and Mitochondrial Protein Synthesis on Insulin Resistant Type 2 Diabetes and Obesity"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...


Searches Linking to this Trial